诺唯赞(688105)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
中泰证券 2024-02-03 买入
浙商证券 2023-12-28 增持
东北证券 2023-11-16 买入
  盈利预测
据诺唯赞三季报分析:

  盈利能力明显恶化,总资产收益能力急剧下降

  成长能力明显恶化,经营业绩承受明显压力

  偿债能力有所削弱,偿还流动负债能力很强

  运营能力明显恶化,总资产利用效率腰斩

  现金流能力维持稳定,公司现金回收质量略差

  财务数据
    截至第三季度实现净利润-0.78亿元,每股收益-0.19元。

    截至第三季度最新股东权益401761.77万元,未分配利润100318.51万元。

    截至第三季度最新总资产571213.96万元,负债169452.19万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入869,295,118571,036,914.17302,194,310.543,568,984,515.62
营业总成本989,192,793.58666,548,736.19350,730,136.652,329,873,423.91
营业利润-97,293,987.61-106,828,104.1-66,825,421.27717,493,845.66
利润总额-108,247,721.97-106,954,270.91-67,988,068.89609,389,800.88
净利润-77,716,085.16-81,988,982.54-51,208,589.27593,506,856.75
其他综合收益-3,114,723.21-3,363,548.621,434,259.87-
综合收益总额-80,830,808.37-85,352,531.16-49,774,329.4593,506,856.75
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计4,213,680,674.844,296,072,597.244,811,049,824.884,565,109,487.88
非流动资产合计1,498,458,894.981,459,864,688.541,507,336,301.351,440,102,266.63
资产总计5,712,139,569.825,755,937,285.786,318,386,126.236,005,211,754.51
流动负债合计1,529,353,902.11,549,272,979.321,539,140,622.171,154,069,118.08
非流动负债合计165,167,948.77189,686,410.06228,544,279.35239,034,455.77
负债合计1,694,521,850.871,738,959,389.381,767,684,901.521,393,103,573.85
归属于母公司股东权益合计4,017,146,301.434,016,074,998.314,548,926,459.634,608,907,358.17
股东权益合计4,017,617,718.954,016,977,896.44,550,701,224.714,612,108,180.66
负债和股东权益合计5,712,139,569.825,755,937,285.786,318,386,126.236,005,211,754.51
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计1,356,086,403.171,051,743,018.58592,476,957.793,379,364,308.55
经营活动现金流出小计1,374,681,385.591,006,971,144.16701,550,351.362,644,198,424.36
经营活动产生的现金流量净额-18,594,982.4144,771,874.42-109,073,393.58735,165,884.19
投资活动现金流入小计3,415,829,373.962,444,995,108.641,297,540,227.939,291,564,670.17
投资活动现金流出小计4,325,255,206.912,413,792,440.261,852,468,133.9410,244,001,741.22
投资活动产生的现金流量净额-909,425,832.9531,202,668.38-554,927,906.01-952,437,071.05
筹资活动现金流入小计1,387,800,0001,114,000,000726,000,000372,000,000
筹资活动现金流出小计979,526,601.32770,460,908.162,974,524.72292,948,700.45
筹资活动产生的现金流量净额408,273,398.68343,539,091.84723,025,475.2879,051,299.55
汇率变动对现金及现金等价物的影响2,519,758.023,071,962.57253,221.895,041,053.77
现金及现金等价物净增加额-517,227,658.66422,585,597.2159,277,397.58-133,178,833.54
期末现金及现金等价物余额827,363,105.31,767,176,361.171,403,868,161.541,344,590,763.96
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润-0.78亿元,每股收益-0.19元。

    截至第三季度最新股东权益401761.77万元,未分配利润100318.51万元。

    截至第三季度最新总资产571213.96万元,负债169452.19万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入869,295,118571,036,914.17302,194,310.543,568,984,515.62
营业总成本989,192,793.58666,548,736.19350,730,136.652,329,873,423.91
营业利润-97,293,987.61-106,828,104.1-66,825,421.27717,493,845.66
利润总额-108,247,721.97-106,954,270.91-67,988,068.89609,389,800.88
净利润-77,716,085.16-81,988,982.54-51,208,589.27593,506,856.75
其他综合收益-3,114,723.21-3,363,548.621,434,259.87-
综合收益总额-80,830,808.37-85,352,531.16-49,774,329.4593,506,856.75
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计4,213,680,674.844,296,072,597.244,811,049,824.884,565,109,487.88
非流动资产合计1,498,458,894.981,459,864,688.541,507,336,301.351,440,102,266.63
资产总计5,712,139,569.825,755,937,285.786,318,386,126.236,005,211,754.51
流动负债合计1,529,353,902.11,549,272,979.321,539,140,622.171,154,069,118.08
非流动负债合计165,167,948.77189,686,410.06228,544,279.35239,034,455.77
负债合计1,694,521,850.871,738,959,389.381,767,684,901.521,393,103,573.85
归属于母公司股东权益合计4,017,146,301.434,016,074,998.314,548,926,459.634,608,907,358.17
股东权益合计4,017,617,718.954,016,977,896.44,550,701,224.714,612,108,180.66
负债和股东权益合计5,712,139,569.825,755,937,285.786,318,386,126.236,005,211,754.51
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计1,356,086,403.171,051,743,018.58592,476,957.793,379,364,308.55
经营活动现金流出小计1,374,681,385.591,006,971,144.16701,550,351.362,644,198,424.36
经营活动产生的现金流量净额-18,594,982.4144,771,874.42-109,073,393.58735,165,884.19
投资活动现金流入小计3,415,829,373.962,444,995,108.641,297,540,227.939,291,564,670.17
投资活动现金流出小计4,325,255,206.912,413,792,440.261,852,468,133.9410,244,001,741.22
投资活动产生的现金流量净额-909,425,832.9531,202,668.38-554,927,906.01-952,437,071.05
筹资活动现金流入小计1,387,800,0001,114,000,000726,000,000372,000,000
筹资活动现金流出小计979,526,601.32770,460,908.162,974,524.72292,948,700.45
筹资活动产生的现金流量净额408,273,398.68343,539,091.84723,025,475.2879,051,299.55
汇率变动对现金及现金等价物的影响2,519,758.023,071,962.57253,221.895,041,053.77
现金及现金等价物净增加额-517,227,658.66422,585,597.2159,277,397.58-133,178,833.54
期末现金及现金等价物余额827,363,105.31,767,176,361.171,403,868,161.541,344,590,763.96
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
国寿成达(上海)健康产业股权投资中心(有限合伙)3095.8018.580.00
杨奇2180.3913.080.00
深圳旦恩先锋投资管理有限公司-深圳旦恩创业投资合伙企业(有限合伙)1477.898.871477.89
南京诺泰投资合伙企业(有限合伙)1266.337.60-96.35
珠海广发信德敖东医药产业股权投资中心(有限合伙)846.815.080.00
杨可婧467.692.810.00
中国银行股份有限公司-华宝中证医疗交易型开放式指数证券投资基金287.131.72-11.22
贾支俊242.701.460.00
深圳市分享成长投资管理有限公司-深圳市分享精准医疗投资合伙企业(有限合伙)213.751.280.00
中国建设银行股份有限公司-浙商丰利增强债券型证券投资基金200.041.200.00
  主力控盘
  公司简介
诺唯赞 所属地域: 江苏省 涉及概念: 基因测序,沪股通,抗原检测,新冠检测,融资融券
主营业务: 生物试剂、酶制试剂研发、生产、销售、技术咨询及技术服务;生化试剂及耗材、机电设备、电子产品销售;自营和代理各类商品及技术的进出口业务(国家限定企业经营或禁止进出口商品和技术的除外)。(依法须经批准的项目,经相关部门批准后方可开展经营活动)一般项目:实验分析仪器销售;实验分析仪器制造;机械设备研发;技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广(除依法须经批准的项目外,凭营业执照依法自主开展经营活动)
上市日期: 2021-11-15 每股净资产: 10.04元 每股收益: -0.19元 净利润: -0.76亿元 净利润增长率: -110.19%
营业收入: 8.69亿元 每股现金流: -0.05元 每股公积金: 6.06元 每股未分配利润: 2.51元 总股本: 4.00亿 流通股: 1.68亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心